Anti-HIV lipopeptide vaccine

Drug Profile

Anti-HIV lipopeptide vaccine

Latest Information Update: 28 Nov 2007

Price : $50

At a glance

  • Originator CNRS; INSERM
  • Developer CNRS; INSERM; sanofi pasteur
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 21 Jan 2005 Aventis Pasteur is now called sanofi pasteur
  • 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
  • 18 Apr 2002 Phase-I clinical trials in HIV infections prevention in France (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top